Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ACLY | P53396 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | ACACA | Q13085 | 1/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | PPARA | Q07869 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | TTR | P02766 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.34 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2278966 | 0.86 | ACACB (0.52) | MEN1KMT2AACLYACACBACACA | |
| SCHEMBL4016071 | 0.83 | MEN1 (0.45) | MEN1KMT2ATSHRTDP1ALDH1A1 | |
| SCHEMBL9086970 | 0.81 | MEN1 (0.44) | MEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL14795068 | 0.81 | MEN1 (0.44) | MEN1KMT2ATDP1ALDH1A1SLC1A2 | |
| SCHEMBL9188074 | 0.77 | MEN1 (0.46) | MEN1KMT2ATSHR | |
| SCHEMBL8961056 | 0.77 | GGT1 (0.50) | MEN1KMT2ATSHRTDP1CYP1A2 | |
| SCHEMBL3530150 | 0.76 | ACLY (0.42) | ACLYACACBACACATBXAS1TSHR | |
| SCHEMBL320771 | 0.76 | ACLY (0.54) | ACLYACACBACACATBXAS1TSHR | |
| SCHEMBL5789155 | 0.75 | — | — | |
| SCHEMBL1342649 | 0.75 | MEN1 (0.52) | MEN1KMT2ATDP1ALDH1A1SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695228-A1 | SYNTHESIS OF RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4695233-A2 | SYNTHESIS OF RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20240383920-A1 | SYNTHESIS OF RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-11-21 | — | — | US | disclosed |
| US-20240368190-A1 | SYNTHESIS OF RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-11-07 | — | — | US | disclosed |
| WO-2024216008-A1 | SYNTHESIS OF RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2024-10-17 | — | — | WO | disclosed |
| WO-2024216017-A2 | SYNTHESIS OF RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2024-10-17 | — | — | WO | disclosed |
| US-8981084-B2 | Oxadiazole HDAC inhibitors | TEMPERO PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8981084-B2 | Oxadiazole HDAC inhibitors | TEMPERO PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20120322827-A1 | COMPOUNDS AND METHODS | TEMPERO PHARAMCEUTICALS. INC. | 2012-12-20 | — | — | US | disclosed |
| EP-2523664-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2012-11-21 | — | — | EP | disclosed |
| EP-2523560-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2012-11-21 | — | — | EP | disclosed |
| US-20120289495-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals Inc. | 2012-11-15 | — | — | US | disclosed |
| US-20120289495-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals Inc. | 2012-11-15 | — | — | US | disclosed |
| WO-2011088187-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011088192-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011088187-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011088192-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383920-A1 | SYNTHESIS OF RAS INHIBITORS | KRAS, NRAS, HRAS | MEN1 530/4885KMT2A 2273/4885ACLY 2952/4885 |
| US-20120322827-A1 | COMPOUNDS AND METHODS | XDH, LPXN, CCNY | MEN1 625/4885KMT2A 2487/4885ACLY 136/4885 |
| US-20240368190-A1 | SYNTHESIS OF RAS INHIBITORS | KRAS, NRAS, HRAS | MEN1 530/4885KMT2A 2273/4885ACLY 2952/4885 |
| US-20120289495-A1 | COMPOUNDS AND METHODS | XDH, CCNY, TOP2B | MEN1 892/4885KMT2A 2762/4885ACLY 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.